The BB9 monoclonal antibody specifically binds Angiotensin-converting enzyme (ACE) which is also known as Dipeptidyl carboxypeptidase 1 (DCP1) or CD143. CD143 is a type I transmembrane glycoprotein that functions as a zinc metallopeptidase involved with the metabolism of angiotensin, bradykinin, and other oligopeptides. It is expressed on primitive hematopoietic progenitor cells (HPC). BB9 reacts with stromal cells, a minor subset of human bone marrow cells; it does not react with peripheral blood leucocytes. BB9 recognizes a subset of CD34+CD90+ cells that demonstrate low or absent expression of CD38, low retention of Rhodamine 123 and are Ki-67-negative. CD34+BB9+ cells are able to sustain hematopoiesis in pre-CFU culture stimulated with IL-3, IL-6, G-CSF, and SCF. BB9 also reacts with a subset of CD34+ cells from mobilized peripheral blood. This antibody was generated using human bone marrow-derived stromal cells as immunogen.
The antibody was conjugated to BD Horizon™ BB700, which is part of the BD Horizon Brilliant™ Blue family of dyes. It is a polymer-based tandem dye developed exclusively by BD Biosciences. With an excitation max of 485 nm and an emission max of 693 nm, BD Horizon BB700 can be excited by the 488 nm laser and detected in a standard PerCP-Cy™5.5 set (eg, 695/40-nm filter). This dye provides a much brighter alternative to PerCP-Cy5.5 with less cross laser excitation off the 405 nm and 355 nm lasers.